PMLS Virtual Series 2022 – Precision Medicine Outside of Oncology
On Demand Now Click Here
March 29, 2022
Welcome and Opening Remarks
Nigel Russell, Director of Events, GenomeWeb
Precision Drug Discovery for Chronic Diseases
Steve Gardner, PhD, Co-founder and Chief Executive Officer, PrecisionLife
In the last decade, fewer than 10% of the targets investigated in drug discovery programs have led to approved drugs. The ‘blockbuster’ discovery strategy does not work well for complex, chronic diseases, leading to expensive late-stage clinical trial failures, mainly due to inability to demonstrate clinical efficacy in patients.
A new precision medicine approach, driven by high-resolution patient stratification insights, goes beyond AI drug discovery to offer a faster, cheaper, and derisked opportunity to bring to market new medicines that address significant pockets of unmet medical need, maximizing the benefits of precision medicines for both drug inventors and patients.
In this presentation, you will learn how this new approach to precision medicine is pioneering the development of better, more personalized therapy options:
- Driving novel target discovery in areas of unmet clinical need
- Identifying new opportunities for existing drugs in novel indications
- Enabling more focused clinical trials to demonstrate efficacy and reduce time to market
Delivering Precision Diagnostics and Genomic Insights Combining Large Data and AI
Bob Vaughan, PhD, Head of Data, Congenica
With the explosion of genomic and phenomic data we present a clinically driven approach to combining large scale data and the predictive capabilities of Congenica’s AI technology to derive both rapid clinical diagnosis of rare disease and potential new avenues of pharmaceutical research.
The Power of AI-Based Computational Histopathology Methods to Improve Clinical Development Effectiveness
Eric Walk, MD, Chief Medical Officer, PathAI
- Understanding common challenges in traditional NASH scoring systems that can impact clinical trial success
- Introduction to PathAI’s AI-based histologic measurement for NASH (AIM-NASH) and how it has been used for accurate, reproducible endpoint assessment
- Discuss additional advances in pathology techniques including continuous scoring of liver biopsy staging and other exploratory features to more sensitively demonstrate drug effect and potentially predict disease progression
- Deriving insights into other disease areas through leveraged learnings from AI-based assessments of NASH histopathology
Leveraging Lessons Learned in Oncology to Support More Personalized Treatment of Neurodegenerative and Metabolic Diseases
Moderator: Mark Roberts, PhD, Senior Director, Labcorp Diagnostics Development
Panelists: Katherine T. Landschulz, PhD, Senior Director, Therapeutic Area Lead – Cardiovascular and Metabolic Disease, Labcorp Biomarker Solution Center; Robert Martone, Associate Director, Neurological Biomarkers, Labcorp Biomarker Solution Center
• Understanding the current landscape of precision medicine and how best practices from the oncology pathway can support neurodegenerative and metabolic disease therapy development
• Unique challenges and advances in biomarker discovery for transforming neurodegenerative research and development
• Exploring biomarkers as candidate diagnostics for complex, multifactorial chronic diseases including non-alcoholic fatty liver disease (fat accumulation in the liver not due to alcohol overconsumption, or NAFLD) and non-alcoholic steatohepatitis (NASH)
Optimizing Medication use Through CMM + PGx in Practice : What is it and how can it be beneficial?
Katherine Capps, President, Health2 Resources; Co-Founder and Executive Director, GTMRx Institute; Ghada Elnashar, PharmD, Associate Director, Medical Affairs, OneOme; GTMRx Workgroup Member
During this session, Katherine H. Capps from the GTMRx Institute and Ghada Elnashar, PharmD, MS from OneOme will illuminate what is comprehensive medication management (CMM) and how can pharmacogenomics (PGx) be utilized as a tool within CMM to optimize medication use, all while providing benefit to the health care team — both clinically and economically. The presentation will also explain how pharmacists can be utilized as the drug expert on the interprofessional care team to help physicians select, manage and monitor their therapeutic regimen. We have the tools and resources already available to optimize medication use and increase efficiency and efficacy. Now the question is: “What do we do with them?”